Latest news for  (OTC:OSGPS) Stock

Mizuho analyst Gabriel Moreen initiates coverage on Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) with a Outperform rating and announces Price Target of $24.

News

Price Target

Initiation

Analyst Ratings

AROC

Mizuho Initiates Coverage On Archrock with Outperform Rating, Announces Price Target of $24

General

OPTT

Ocean Power Technologies Announces $1.1M Preliminary Award From New Jersey Economic Development Authority Technology Business Tax Certificate Transfer Program

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group.
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a post hoc analysis of the Phase 1b/2a clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal. The publication, entitled, "Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis," is available on the Journal's website and at: <a href="https://www.globenewswire.com/Tracker?data=c_v8cCCIXPOR4To7b2WxX6bKRBPcr0zlsbLBnVvP464Lo7lVB-HQRVAP93dW8kINVxrVPODmoG1nEfyc5w0X5WoY5x767tNJU5XCEFyXoxHgA45s1Bk1Hs_xlYd1RbfVlyVQIsd8GLfEY-BHeJSJRg==">https://doi.org/10.1183/23120541.00536-2024</a>.

Biotech

ATYR

aTyr Pharma Announces Publication Demonstrating Efficacy Of Efzofitimod In Pulmonary Sarcoidosis In The European Respiratory Journal

Macro Economic Events

Macro Notification

Econ #s

Economics

USA ADP Nonfarm Employment Change For September 143K Vs 124K Est.; 103K Prior

– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study –
– Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe –
– Data From the MILOS German Cohort Showed Bempedoic Acid, Alone or With Ezetimibe, Was Effective and Had A Safety Profile in Real-World Settings Consistent With the CLEAR Outcomes Study –
ANN ARBOR, Mich., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) today announced that its European partner, Daiichi Sankyo Europe (DSE), reported final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study. The European study evaluated the real-world use of bempedoic acid, marketed as NILEMDO&#xAE;&nbsp;in the EU and bempedoic acid and ezetimibe, marketed as NUSTENDI&#xAE; in the EU, in patients with primary hypercholesterolemia or mixed dyslipidemia. The products are marketed as NEXLETOL&#xAE; (bempedoic acid) and NEXLIZET&#xAE;&nbsp;(bempedoic acid and ezetimibe) in the U.S.
The results, presented in Hamburg, Germany at DGK Herztage 2024, demonstrated the effectiveness and safety profile of bempedoic acid, both alone and in combination with other lipid-lowering therapies (LLTs) in clinical practice. Raised LDL-C is a key modifiable contributor to risk of major cardiovascular events, with studies showing that every 1 mmol/L reduction in LDL-C is associated with a 22% reduction in major cardiovascular events after one year.
The German cohort of the MILOS study comprising 973 patients from 125 sites in Germany, is one of the most comprehensive assessments of bempedoic acid in a real-world clinical setting to-date in Germany.&nbsp;Patients were followed-up for two years, with LDL-C levels assessed at pre-treatment, one year (1Y) and two years (2Y). Overall, 638 of 973 patients (65.6%) completed 2Y follow up, with LDL-C values at pre-treatment, 1Y and 2Y available for 451 patients. In these 451 patients, a mean reduction of LDL-C levels from 3.1 mmol/L (121.4 mg/dL) at pre-treatment, to 2.0 mmol/L (77.2 mg/dL) was observed, representing an average relative reduction of 30.3% in the overall population.
Additionally, the percentage of patients reaching their LDL-C goals increased from 4.9% at pre-treatment to 35.3% at the 2Y follow-up – an approximately 7-fold increase.&nbsp;The proportions of high-risk and very high-risk patients reaching LDL-C goals increased from 5.6% to 32.5%, and 3.6% to 35.2%, respectively.
Overall, more than 80% of patients received bempedoic acid in combination with other LLTs at pre-treatment and 2Y, including statins and ezetimibe. The safety profile of bempedoic acid in this real-world population was assessed at 1Y and 2Y and was consistent with that observed in the CLEAR clinical trial program.&nbsp;

ESPR

Esperion EU Partner Reports Final Real-World Results From MILOS German Cohort Demonstrating Strong Increase In LDL-C Goal Achievement With Addition Of Bempedoic Acid

Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food &amp; Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare &amp; Medicaid Services (CMS) in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months.&nbsp;&nbsp;

TCMD

Tactile Medical Technology Announces That Nimbl, Its Next-Generation Pneumatic Compression Platform, Is Now Commercially Available Throughout The U.S. For The Treatment Of Upper Extremity Lymphedema

Morgan Stanley analyst James Faucette maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Equal-Weight and raises the price target from $122 to $133.

PAYX

Morgan Stanley Maintains Equal-Weight on Paychex, Raises Price Target to $133

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $3 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $3 Price Target

IM Cannabis Corp. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#CSE">IMCC</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products.
 &nbsp;

CSE:IMCC

IMCC

IMC Germany Announces Preliminary Q3, 2024 Showing A 50% Increase In Revenue Compared To Q2, Where IMC Germany Sold About CAD$ 3.5M

Google DeepMind by Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) and BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) are collaborating to develop AI lab assistants aimed at enhancing scientific research.
What Happened: Sir Demis Hassabis, head of Google&#8217;s AI division, is spearheading the creation of an AI model designed to function as a research assistant. This AI aims to facilitate interdisciplinary collaboration and uncover unexpected connections in scientific research, Financial Times <a href="https://www.ft.com/content/64b1bb33-095e-4cc5-a911-50df76fa3d1d">reported</a> on Wednesday.
At a recent Nobel Foundation event, Hassabis highlighted the transformative impact of AI on biology, stating, &#8220;We're working on a science large language model that could be like a research assistant and maybe help you predict the outcome of an experiment.&#8221;
Meanwhile, BioNTech and its AI subsidiary InstaDeep introduced an AI assistant named Laila, built on Meta's Llama 3.1 model. During a live demonstration, research scientist Arnu Pretorius showcased Laila&#8217;s capabilities in automating routine tasks in experimental biology.
InstaDeep's CEO Karim Beguir emphasized that AI agents like Laila are intended to boost productivity, allowing scientists to focus on critical tasks. The AI models presented by InstaDeep also aim to assist BioNTech in identifying new targets for cancer treatment.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/41005364/using-weed-while-pregnant-study-of-500k-people-reveals-surprising-findings-some-better-than-othe?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Using Weed While Pregnant: Study Of 500k People Reveals Surprising Findings—Some Better Than Others</a>
Why It Matters: Google DeepMind&#8217;s shift from a research-centric entity to an <a href="https://www.benzinga.com/markets/equities/24/06/39370675/googles-deepmind-shifting-from-research-powerhouse-to-ai-product-giant-redefining-industry-dynam">AI product powerhouse</a> is a significant development in the tech industry. This transition, reported in June, signifies a strategic pivot to commercial services, potentially disrupting traditional research paradigms.
In May, Google DeepMind introduced AlphaFold 3, an <a href="https://www.benzinga.com/general/biotech/24/05/38711266/google-deepmind-develops-latest-ai-model-to-aid-scientists-in-fighting-disease">AI model capable </a>of predicting the structure and interactions of biological molecules, including proteins and DNA. This model is available for non-commercial use, aiding scientists in disease research.
On the other hand, BioNTech has <a href="https://www.benzinga.com/general/biotech/24/08/40157789/biontechs-q2-loss-widens-amid-low-demand-for-its-pfizer-partnered-covid-19-vaccine-increases-r-d-">faced financial challenges</a>, reporting deeper losses in Q2 2024 due to reduced demand for its COVID-19 vaccine. The company has increased R&amp;D spending on new cancer treatments, highlighting the importance of innovative solutions like AI to drive future growth.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, GOOGL closed at $166.99 while GOOG ended at $168.42. BioNTech closed at $119.93.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/41091446/cvs-health-in-focus-as-activist-investor-prepares-for-high-level-talks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CVS Health in Focus as Activist Investor Prepares for High-Level Talks</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Health Care

Tech

BNTX

GOOG

GOOGL

Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research

Morgan Stanley analyst Brian Nowak maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) with a Equal-Weight and raises the price target from $46 to $60.

Morgan Stanley Maintains Equal-Weight on Zillow Gr, Raises Price Target to $60

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

MARA Sept. Energized Hash Rate Increased 5% To 36.9 EH/s, BTC Production Grew 5% To 705 BTC

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Magnite Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>)</h3>
<ul>
<li>On Oct. 2, Needham analyst Laura Martin reiterated Magnite with a Buy and maintained a $15 price target. The company's stock fell around 8% over the past month and has a <a href="https://www.benzinga.com/quote/MGNI">52-week low of $6.28</a>.</li>
<li>RSI Value: 29.99</li>
<li>MGNI Price Action: Shares of Magnite fell 10.8% to close at $12.36 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">atest MGNI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080326/image-3.png" alt="" class="wp-image-576316" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080326/image-3.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080326/image-3-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080326/image-3-768x714.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Shutterstock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>In an exchange filing on Aug. 22, the company notified John Caine that his employment as its Chief Product and Digital Officer will end, effective Aug. 23, 2024. Caine joined the company as Global Head of E-Commerce on January 30, 2023. The company's stock fell around 6% over the past five days. It <a href="https://www.benzinga.com/quote/ALCE">has a 52-week low</a> of $32.38.</li>
<li>RSI Value: 28.00</li>
<li>SSTK Price Action: Shares of Shutterstock fell 7.2% to close at $32.81 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">trend in SSTK stoc</a>k.</li>
</ul>
<h3 class="wp-block-heading">Eventbrite Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>)</h3>
<ul>
<li>Eventbrite, on Aug. 21, announced that it engaged in repurchase transactions for of its 5.00% Convertible Senior Notes. The company's shares fell around 14% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/EB">low of $2.51</a>.</li>
<li>RSI Value: 26.12</li>
<li>EB Price Action: Shares of Eventbrite fell 3.3% to close at $2.64 on Tuesday.</li>
<li>Benzinga Pro&#8217;s insiders feature was used to tracking insider t<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1">rading in EB shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="898" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080645/image-2-2.png" alt="" class="wp-image-576328" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080645/image-2-2.png 898w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080645/image-2-2-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/02080645/image-2-2-768x715.png 768w" sizes="(max-width: 898px) 100vw, 898px" /></a></figure>
Read Next:<a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/41102060/jim-cramer-hand-picks-these-3-stocks-to-ride-the-crest-of-the-chinese-stimulus-frenzy">Jim Cramer Hand Picks These 3 Stocks To Ride The Crest Of The Chinese Stimulus Frenzy</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

MGNI

SSTK

Top 3 Tech And Telecom Stocks That May Surge This Month

Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares are trading lower premarket on Wednesday. The company disclosed plans to invest over $6.5 billion to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41133324/oracle-to-invest-more-than-us-6-5-billion-in-ai-and-cloud-computing-in-malaysia" rel="noreferrer noopener">open a public cloud region in Malaysia</a>.
The company aims to meet the country&#8217;s growing demand for AI and cloud services.
This new cloud region will allow Oracle&#8217;s customers and partners in Malaysia to access AI infrastructure, services, and migrate critical workloads to Oracle Cloud Infrastructure (OCI).
Oracle plans to open a cloud region in Malaysia, offering over 150 infrastructure and SaaS services to boost the country&#8217;s digital economy and drive AI innovation.
This new cloud region will expand OCI&#8217;s presence in the Asia Pacific to 12 public cloud regions.
YB Senator Tengku Datuk Seri Utama Zafrul Tengku Abdul Aziz, minister of investment, trade and industry&nbsp;(MITI),&nbsp;Malaysia said, &#8220;It is also a significant step towards realising the country&#8217;s New Industrial Master Plan&#8217;s ambitious vision of creating 3,000 smart factories by 2030.&#8221;
Garrett Ilg, executive vice president and general manager,&nbsp;Japan&nbsp;&amp;&nbsp;Asia Pacific, Oracle added, &#8220;Our multi-billion dollar investment affirms our commitment to&nbsp;Malaysia&nbsp;as a regional gateway for cloud infrastructure as well as a comprehensive suite of SaaS applications deployed within&nbsp;Malaysia.&#8221;
Read: <a target="_blank" href="https://www.benzinga.com/top-stories/24/09/40937593/oracle-cloudworld-highlights-ai-driven-tech-services-but-revenue-growth-requires-patience-analyst" rel="noreferrer noopener">Oracle CloudWorld Highlights &#8216;AI-Driven Tech Services,&#8217; But Revenue Growth Requires Patience: Analyst</a>
Notably, IDC FutureScape&#8217;s &#8216;The Infrastructure and Cloud Impact 2024 Predictions&#8217; forecasts Malaysia&#8217;s public cloud services market to grow at a 27.2% CAGR from 2022 to 2027.
Last month, the company announced several new partnerships with various companies, including contracts&nbsp;with Guardian Life, Anduril, and RAFAEL enhancing Oracle&#8217;s cloud and AI capabilities, driving efficiency and innovation.
Investors can gain exposure to Oracle through&nbsp;iShares Expanded Tech-Software Sector ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and&nbsp;Pacer Funds Pacer Data and Digital Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRFK#NYSE">TRFK</a>).
Price Action: ORCL shares are down 0.04% at $167.10 premarket at the last check Wednesday.
Photo: Michael Vi/Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/41002243/oracle-surges-20-in-september-as-ai-cloud-strategy-flashes-bullish-signals" target="_blank" rel="noreferrer noopener">Oracle Surges 20% In September As AI, Cloud Strategy Flashes Bullish Signals</a></li>
</ul>

Equities

Large Cap

ORCL

TRFK

Oracle Bets Big: Plans Over $6.5B Cloud Expansion In Malaysia To Fuel AI Innovation

ESTA

Establishment Labs Announces First U.S. Breast Augmentations Using Newly FDA-Approved Motiva Implants

For Q3 2024, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268904-1&amp;h=3042681741&amp;u=http%3A%2F%2Fwww.nikolamotor.com%2F&amp;a=Nikola+Corporation">Nikola Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268904-1&amp;h=2626431908&amp;u=https%3A%2F%2Fwww.nikolamotor.com%2Fpress_releases%2Fnikola-highlights-its-integrated-hydrogen-solution-and-introduces-new-hydrogen-energy-brand-hyla-227%2F&amp;a=HYLA+brand">HYLA brand</a>, wholesaled 88 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268904-1&amp;h=2979377408&amp;u=https%3A%2F%2Fnikolamotor.com%2Ftre-fcev%2F&amp;a=Class+8+Nikola+hydrogen+fuel+cell+electric+trucks">Class 8 Nikola hydrogen fuel cell electric trucks</a>, firmly within truck sales guidance of between 80 and 100 fuel cell units for the quarter.
&nbsp;
&nbsp;

NKLA

Nikola Announced Sales Of 88 Hydrogen-powered Class 8 Trucks For North American Customers In Q3 2024

Charles River And Lundbeck Partner To Use AI-Powered Logica Platform For Advancing Neurological Disease Drug Discovery

Morgan Stanley analyst Brian Harbour maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Overweight and raises the price target from $515 to $520.

Morgan Stanley Maintains Overweight on Domino's Pizza, Raises Price Target to $520

URGN

UroGen Pharma Doses First Patient In Phase 3 Trial Of UGN-103 For Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, Featuring Improved Manufacturing And Reconstitution Process

ImmunoPrecise Antibodies And Biotheus Enter Agreement To Evaluate AI-Enhanced Talem Antibody For Development Of Bispecific Therapy Targeting Hypoxic Solid Tumors

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

News

Latest news for (OTC:OSGPS) Stock